# Who does AbbVie pay? Who are its key suppliers?
Canonical: https://valuechain.wiki/abbvie · Facet: suppliers · Updated: 2026-10-09T16:09:06.345+00:00 · Source: ValueChain.wiki (cited money-flow graph)

**Citable summary**: AbbVie's confirmed suppliers/cost counterparties include AbCellera plus 2 undisclosed/aggregate relationships. Per the valuechain.wiki graph: 3 cost edges, backed by 4 dated sources, 2 of them primary filings (as of 2026-10-09).

### 원료의약품·위탁생산(API·CDMO) 공급망 (high)
- metric: Amount $18.2B · FY2025 Cost of products sold · Cost of products sold $18,204M
- note: Cost of products sold $18.2B. AbbVie sources raw materials from numerous global suppliers and contracts third parties for API, product manufacturing, fill/finish and packaging, avoiding single-source dependence with alternate supply relationships.
- [confirms] SEC EDGAR (EN, filing, published 2026-02-20) https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/abbv-20251231.htm: ""Cost of products sold 18,204 ... AbbVie has agreements with third parties for active pharmaceutical ingredient and product manufacturing, formulation and development services, fill, finish and packaging services ... In most cases, AbbVie maintains alternate supply relationships.""

### 연구개발·라이선스인(R&D·IPR&D) (high)
- metric: Amount $9.1B · FY2025 R&D · R&D $9,096M; Acquired IPR&D $5,016M
- note: R&D expense $9.1B plus acquired IPR&D and milestones $5.0B make pipeline investment the largest cost axis, defending post-Humira growth through in-licensing/acquisitions (e.g., Elahere) and internal R&D.
- [confirms] SEC EDGAR (EN, filing, published 2026-02-20) https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/abbv-20251231.htm: ""Research and development 9,096 ... Acquired IPR&D and milestones 5,016 ... AbbVie makes a significant investment in research and development.""

### AbCellera (high)  → /abcellera.md
- note: AI antibody-discovery partner: up to five targets from December 2022, expanded to oncology T-cell engagers in January 2025. AbbVie pays upfront and research fees plus milestones and royalties; amounts undisclosed.
- [confirms] SEC EDGAR (AbCellera 10-K) (EN, filing, published 2026-02-24) https://www.sec.gov/Archives/edgar/data/1703057/000170305726000012/abcl-20251231.htm: "AbCellera 10-K partnership table: "AbbVie Inc. Multi-target, multi-year Oncology January 13, 2025"; "AbbVie Inc. Up to 5 targets, multi-year Undisclosed December 15, 2022"."
- [confirms] Business Wire (EN, news, published 2025-01-13) https://www.businesswire.com/news/home/20250113347375/en/AbCellera-Expands-Collaboration-with-AbbVie-to-Develop-Novel-T-Cell-Engagers-for-Oncology: "AbCellera "has expanded its existing collaboration with AbbVie Inc. (NYSE: ABBV) to include the discovery of T-cell engagers (TCE) in oncology"."
- [confirms] Business Wire (EN, news, published 2022-12-15) https://www.businesswire.com/news/home/20221215005196/en/AbCellera-and-AbbVie-Partner-to-Advance-New-Antibody-Therapies/: ""...optimized development candidates for up to five targets selected by AbbVie...""

Reverse side: https://valuechain.wiki/abbvie/customers.md · Ripple: https://valuechain.wiki/abbvie/ripple.md

---
Full node: https://valuechain.wiki/abbvie.md · JSON: https://valuechain.wiki/abbvie.json